Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;46(5):231.
doi: 10.3892/or.2021.8182. Epub 2021 Sep 9.

Metastatic pancreatic cancer: Mechanisms and detection (Review)

Affiliations
Review

Metastatic pancreatic cancer: Mechanisms and detection (Review)

Xiangling Chen et al. Oncol Rep. 2021 Nov.

Abstract

Pancreatic cancer (PC) is a lethal malignancy. Its prevalence rate remains low but continues to grow each year. Among all stages of PC, metastatic PC is defined as late‑stage (stage IV) PC and has an even higher fatality rate. Patients with PC do not have any specific clinical manifestations. Most cases are inoperable at the time‑point of diagnosis. Prognosis is also poor even with curative‑intent surgery. Complications during surgery, postoperative pancreatic fistula and recurrence with metastatic foci make the management of metastatic PC difficult. While extensive efforts were made to improve survival outcomes, further elucidation of the molecular mechanisms of metastasis poses a formidable challenge. The present review provided an overview of the mechanisms of metastatic PC, summarizing currently known signaling pathways (e.g. epithelial‑mesenchymal transition, NF‑κB and KRAS), imaging that may be utilized for early detection and biomarkers (e.g. carbohydrate antigen 19‑9, prostate cancer‑associated transcript‑1, F‑box/LRR‑repeat protein 7 and tumor stroma), giving insight into promising therapeutic targets.

Keywords: biomarker; mechanism; pancreatic cancer metastasis; signaling pathway.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1.
Figure 1.
Major signaling pathways in metastatic pancreatic cancer. EMT, epithelial-mesenchymal transition; ΝF-κΒ, nuclear factor-κ-light-chain-enhancer activated B cells; GDP, guanosine diphosphate; GTP, guanosine triphosphate; GAP, GTPase-activating protein; GEF, guanine nucleotide exchange factor; cGAS, cyclic GMP-AMP synthase; STING, stimulator of interferon genes; TBK1, TANK binding kinase-1; PI3K, phosphatidylinositol 3-kinase; IKK, inhibitor of ΝF-κΒ kinase; MEK, MAPK/ERK kinase; Erk, extracellular signal-regulated protein kinase; MLK3, mixed lineage kinase 3; TAK, transforming growth factor β-activated kinase; DLK, dual-leucine zipper kinase; P38 MAPK, P38 mitogen-activated protein kinase; MKK, MAP kinase kinase; SAPK/JNK, stress-activated protein kinase/c-Jun N-terminal kinase; MEKK, MEK kinase; BMK1, big MAP kinase 1.

References

    1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol. 2019;10:10–27. doi: 10.14740/wjon1166. - DOI - PMC - PubMed
    1. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15:333–348. doi: 10.1038/s41575-018-0005-x. - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. doi: 10.3322/caac.21601. - DOI - PubMed
    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer Statistics, 2006. CA Cancer J Clin. 2006;56:106–130. doi: 10.3322/canjclin.56.2.106. - DOI - PubMed
    1. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24:792–800. doi: 10.1093/annonc/mdt010. - DOI - PubMed

MeSH terms

Substances